Who
Daphne Quimi
Director
Company insider
Files Form 4 as: Director, Century Therapeutics; Director, Amylyx Pharmaceuticals; Chief Financial Officer, Amicus Therapeutics.
In numbers
- Trades disclosed
- 146
- Buys
- 6
- Sells
- 21
- Bought
- $158K
- Sold
- $1.7M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 4 Jun 2012
- Last trade
- 11 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 12 Jun 2026 | IPSC Century Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | IPSC Century Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,000 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,372 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,372 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | IPSC Century Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 12 Sep 2024filed 16 Sep 2024 | IPSC Century TherapeuticsBiotechnology | SEC FORM 4 Bought | $7,6505,000 at $1.53 | filing |
| 20 Jun 2024filed 21 Jun 2024 | IPSC Century Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 15 May 2024filed 16 May 2024 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $4,2532,250 at $1.89 | filing |
| 14 May 2024filed 16 May 2024 | AMLX Amylyx PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $5,1982,750 at $1.89 | filing |
| 27 Jun 2023filed 29 Jun 2023 | IPSC Century Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 8 Jun 2023filed 12 Jun 2023 | AMLX Amylyx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,985 at $0.00 | filing |
| 18 Jan 2023filed 19 Jan 2023 | Amicus Therapeutics | SEC FORM 4 Sold | $90K6,923 at $13.00 | filing |
| 17 Jan 2023filed 19 Jan 2023 | Amicus Therapeutics | SEC FORM 4 Sold | $62K5,000 at $12.49 | filing |
| 11 Jan 2023filed 13 Jan 2023 | Amicus Therapeutics | SEC FORM 4 Code A | —58,824 at $0.00 | filing |
| 11 Jan 2023filed 13 Jan 2023 | Amicus Therapeutics | SEC FORM 4 Code F | $355K29,565 at $12.02 | filing |
| 4 Jan 2023filed 6 Jan 2023 | Amicus Therapeutics | SEC FORM 4 Code F | $47K3,884 at $12.03 | filing |
| 3 Jan 2023filed 4 Jan 2023 | Amicus Therapeuticsoption or derivative | SEC FORM 4 Code A | —130,480 at $0.00 | filing |
| 3 Jan 2023filed 4 Jan 2023 | Amicus Therapeutics | SEC FORM 4 Code A | —73,508 at $0.00 | filing |
News
Denali Therapeutics (NASDAQ:DNLI) vs. Century Therapeutics (NASDAQ:IPSC) Head-To-Head ContrastIPSC · themarketsdaily.com · 19 Oct 2026Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $39.00AMLX · dailypolitical.com · 18 Oct 2026Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in LondonIPSC · manilatimes.net · 14 Oct 2026Century Therapeutics (NASDAQ:IPSC) vs. Burning Rock Biotech (NASDAQ:BNR) Head to Head ContrastIPSC · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Daphne Quimi; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.